Bolt Biotherapeutics, Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Bolt Biotherapeutics (parent company in merger) is acquiring Prana Therapies in a two-step merger. Bolt will issue 430,746 shares of common stock and 16,360.929 shares of Series D Convertible Preferred Stock to Prana stockholders. The deal includes a concurrent $[amount not specified in filing] Series D financing from third-party investors. Closing occurs immediately upon execution. Company shareholders already approved by written consent; parent stockholder votes pending.
Why this rating
Large relative to Bolt's ~$7.3M market cap; merger materially alters ownership/capital structure. Positive: adds Prana assets/IP; raises capital. Execution risk on stockholder approvals and financing.
Tradability signal
NO TRADE
No trade: positive news with only +1.5% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.38% over 4 hrs, n=234).
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $6.68 ▼ 1.50% | at our read · unknown $6.78 | +10 min · unknown $7.09 ▲ 4.62% | +30 min · unknown $6.95 ▲ 2.48% | +1 hr · unknown $7.20 ▲ 6.16% | +4 hrs pending |
The stock had already moved +1.53% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.